[
    [
        {
            "time": "2021-08-13",
            "original_text": "药明康德(603259)：CXO龙头 迭创新高",
            "features": {
                "keywords": [
                    "药明康德",
                    "CXO",
                    "龙头",
                    "创新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259)：CXO龙头 迭创新高",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "天风证券维持药明康德买入评级：2021H1业绩超预期，增长动力强劲",
            "features": {
                "keywords": [
                    "天风证券",
                    "药明康德",
                    "买入评级",
                    "业绩超预期",
                    "增长动力强劲"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券维持药明康德买入评级：2021H1业绩超预期，增长动力强劲",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "药明康德上半年营收超百亿，近30亿营收来自全球20大制药企",
            "features": {
                "keywords": [
                    "药明康德",
                    "营收超百亿",
                    "全球20大制药企"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德上半年营收超百亿，近30亿营收来自全球20大制药企",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "年内上市公司理财规模达7664亿 传统结构性存款和银行理财仍是主战场",
            "features": {
                "keywords": [
                    "上市公司",
                    "理财规模",
                    "结构性存款",
                    "银行理财"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "年内上市公司理财规模达7664亿 传统结构性存款和银行理财仍是主战场",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "光大证券：维持药明康德(603259.SH)“买入”评级 临床前CRO及CDMO业务持续高速发展",
            "features": {
                "keywords": [
                    "光大证券",
                    "药明康德",
                    "买入评级",
                    "临床前CRO",
                    "CDMO",
                    "高速发展"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "光大证券：维持药明康德(603259.SH)“买入”评级 临床前CRO及CDMO业务持续高速发展",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "招商证券：维持药明康德(603259.SH)“强烈推荐-A”评级 CDMO业务高速增长",
            "features": {
                "keywords": [
                    "招商证券",
                    "药明康德",
                    "强烈推荐-A",
                    "CDMO",
                    "高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "招商证券：维持药明康德(603259.SH)“强烈推荐-A”评级 CDMO业务高速增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "国泰君安：维持药明康德(603259.SH)“增持”评级 目标价195元",
            "features": {
                "keywords": [
                    "国泰君安",
                    "药明康德",
                    "增持评级",
                    "目标价195元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国泰君安：维持药明康德(603259.SH)“增持”评级 目标价195元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-13",
            "original_text": "药明康德（603259）2021年中报点评：业绩超市场预期，合全药业CDMO业务驱动高增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "中报",
                    "业绩超预期",
                    "CDMO",
                    "高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德（603259）2021年中报点评：业绩超市场预期，合全药业CDMO业务驱动高增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]